Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Other Non Operating Income came in at -$39000.0 in Q4 2025, down 165.0% year-on-year from $60000.0 in Q4 2024, and up 15.22% on a QoQ basis from -$46000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Other Non Operating Income data on file, last reported at -$39000.0 in Q4 2025.
- On a quarterly basis, Other Non Operating Income fell 165.0% year-over-year to -$39000.0 in Q4 2025; TTM through Dec 2025 was -$381000.0, a 608.0% decrease from a year earlier, with the FY2025 full-year figure at -$381000.0, down 608.0% from the prior year.
- Other Non Operating Income for Q4 2025 stood at -$39000.0, up from -$46000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for INBX reached as high as $60000.0 in Q4 2024 and fell as low as -$246000.0 in Q2 2025.
- Historically, Other Non Operating Income has averaged -$74181.8 across 3 years, with a median of -$50000.0 in 2025.
- Across the five-year window, Other Non Operating Income surged 137.97% in 2024 and tumbled 845.45% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at -$158000.0 in 2023, then jumped by 137.97% to $60000.0 in 2024, then tumbled by 165.0% to -$39000.0 in 2025.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$39000.0 in Q4 2025, -$46000.0 in Q3 2025, and -$246000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -246,000.00 |
| Mar 31, 2025 | -50,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | -59,000.00 |
| Dec 31, 2023 | -158,000.00 |
| Sep 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -217,000.00 |